High-risk Myelodysplastic neoplasia, Acute myeloid leukemia research hub

Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)

This study looks at a new drug, Magrolimab, combined with standard chemotherapy for adults with newly diagnosed, higher-risk Acute Myeloid Leukemia (AML) who are planning to have a stem cell transplant. It aims to see how well this combination works in getting the disease under control.